ADCT - ADC Therapeutics SA

NYSE - Nasdaq Real Time Price. Currency in USD
36.33
-0.62 (-1.68%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close36.95
Open36.79
Bid36.48 x 800
Ask36.59 x 1200
Day's Range35.39 - 37.56
52 Week Range28.50 - 37.98
Volume213,498
Avg. Volume896,000
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Business Wire

      ADC Therapeutics Announces Loncastuximab Tesirine (Lonca) Clinical Data to be Presented at the Virtual 25th EHA Annual Congress

      ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients suffering from hematological malignancies and solid tumors, announced today that interim clinical data on loncastuximab tesirine (Lonca, formerly ADCT-402) will be presented in an oral presentation and e-Poster at the virtual 25th Congress of the European Hematology Association (EHA25).

    • Business Wire

      ADC Therapeutics Announces Closing of Upsized $267 Million Initial Public Offering and Receipt of the $65 Million First Tranche under Its $115 Million Convertible Credit Facility with Deerfield

      ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients suffering from hematological malignancies and solid tumors, announced today the closing of its initial public offering of 14,082,475 shares of its common shares at a price of $19.00 per share, which included the exercise in full by the underwriters of their option to purchase 1,836,844 additional common shares. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by ADC Therapeutics, are approximately $267.6 million. The shares began trading on the New York Stock Exchange on May 15, 2020 under the ticker symbol "ADCT."

    • MarketWatch

      ADC Therapeutics stock soars 56% in trading debut

      ADC Therapeutics S.A. shares rocketed 56% Friday in their trading debut, after the Swiss biotech's initial public offering priced above its proposed price range and underwriters increased the size of the deal. The company sold 12.2 million shares priced at $19 each, above the price range of $16 to $18, to raise $233 million with proceeds to be used to fund clinical research. The stock is trading on the NYSE under the ticker symbol "ADCT." Morgan Stanley, BofA Securities and Cowen were the lead underwriters on the deal. The company recorded a net loss of $116.5 million on contract revenue of $2.3 million in 2019, compared with a loss of $123.1 million on revenue of $1.1 million in 2018.

    • MarketWatch

      ADC Therapeutics prices IPO at $19 a share, above the price range

      ADC Therapeutics S.A. priced its initial public offering at $19 a share late Thursday, above its proposed price range of $16 to $18, and increased the size to 12.2 million shares from 10.3 million when it set terms. The Swiss biotechnology company focused on cancer treatments raised $233 million with proceeds to be used to fund clinical research. The stock will start trading on the NYSE later Friday under the ticker symbol "ADCT." Morgan Stanley, BofA Securities and Cowen were the lead underwriters on the deal. The company recorded a net loss of $116.5 million on contract revenue of $2.3 million in 2019, compared with a loss of $123.1 million on revenue of $1.1 million in 2018. ADC is going public at a time that the Renaissance IPO ETF has slipped 4% over the past three months while the S&P 500 has dropped 16%.

    • GlobeNewswire

      ADC Therapeutics Announces Pricing of Upsized Initial Public Offering

      LAUSANNE, Switzerland, May 14, 2020 -- ADC Therapeutics SA, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of.

    • MarketWatch

      ADC Therapeutics sets IPO terms, to be valued at up to $1 billion

      ADC Therapeutics S.A. set terms of its initial public offering, as the Switzerland-based biotechnology company focused on cancer treatments looks to raise up to $185.3 million. ADC is offering 10,295,000 shares in the IPO, which is expected to price between $16 and $18. With 56.58 million shares outstanding after the IPO, the company could be valued at $1.02 billion if the IPO prices at $18. The stock will be listed on the NYSE under the ticker symbol "ADCT." Morgan Stanley, BofA Securities and Cowen are the lead underwriters. The company recorded a net loss of $116.5 million on contract revenue of $2.3 million in 2019, compared with a loss of $123.1 million on revenue of $1.1 million in 2018. ADC is looking to go public at a time that the Renaissance IPO ETF has slipped 5.1% over the past three months while the S&P 500 has dropped 16.6%.